ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer (MIBC). Now, detailed data show exactly how Imfinzi performed, as the company’s chief medical officer defends the immunotherapy’s continued use on both sides of surgery.